Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RET | P07949 | 7/20 | 0.52 |
| ▸ | JAK3 | P52333 | 2/20 | 0.44 |
| ▸ | CRBN | Q96SW2 | 2/20 | 0.42 |
| ▸ | DDB1 | Q16531 | 1/20 | 0.42 |
| ▸ | PPARG | P37231 | 1/20 | 0.41 |
| ▸ | HRH3 | Q9Y5N1 | 2/20 | 0.41 |
| ▸ | GRM1 | Q13255 | 1/20 | 0.40 |
| ▸ | GPR119 | Q8TDV5 | 1/20 | 0.39 |
| ▸ | NTRK1 | P04629 | 1/20 | 0.39 |
| ▸ | ME2 | P23368 | 1/20 | 0.39 |
| ▸ | ME1 | P48163 | 1/20 | 0.39 |
| ▸ | ME3 | Q16798 | 1/20 | 0.39 |
| ▸ | TRPC6 | Q9Y210 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31713482 | 0.87 | RET (0.52) | RETJAK3CRBNDDB1PPARG | |
| SCHEMBL31713817 | 0.85 | GPR119 (0.44) | RETJAK3GPR119TRPC6 | |
| SCHEMBL31401286 | 0.83 | RET (0.47) | RETJAK3HRH3GPR119NTRK1 | |
| SCHEMBL16540062 | 0.82 | JAK3 (0.43) | RETJAK3GRM1GPR119 | |
| SCHEMBL31713462 | 0.82 | GPR119 (0.56) | RETJAK3GPR119 | |
| SCHEMBL31401450 | 0.82 | RET (0.46) | RETJAK3CRBNGPR119NTRK1 | |
| SCHEMBL31713408 | 0.81 | JAK3 (0.46) | RETJAK3GPR119NTRK1TRPC6 | |
| SCHEMBL31713438 | 0.81 | JAK3 (0.47) | RETJAK3GPR119 | |
| SCHEMBL29516541 | 0.81 | USP30 (0.51) | RETJAK3CRBNDDB1GPR119 | |
| SCHEMBL18390058 | 0.81 | USP30 (0.51) | RETJAK3CRBNDDB1GPR119 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250333406-A1 | SULFONYL CYCLIC DERIVATIVES, AND COMPOSITIONS AND METHODS THEREOF | LYSOWAY THERAPEUTICS INC (US) | 2025-10-30 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250333406-A1 | SULFONYL CYCLIC DERIVATIVES, AND COMPOSITIONS AND METHODS THEREOF | STOML2, ATP2A3, ATP2A1 | RET 1558/4885JAK3 4635/4885CRBN 1323/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.